CESX yields 666666.67% · ABBV yields 3.06%● Live data
📍 CESX pulled ahead of the other in Year 1
Combined, CESX + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CESX + ABBV for your $10,000?
CES Synergies, Inc., an asbestos and lead abatement contracting firm, engages in the removal of asbestos and lead from buildings and other structures, and demolition of structures in the United States. It operates through three segments: Remediation, Demolition, and Insulation. The Remediation segment engages in the asbestos abatement, lead removal, mold remediation, and indoor air quality/duct cleaning activities; and removal of contaminated soil, animal waste removal, manual selective and complete interior demolition comprising removal of floor covering, and adhesive removal services for commercial, retail, governmental, industrial, military, and public and private schools. The Demolition segment is involved in the building separations, concrete breaking, and saw-cutting using its own man-lifts, bobcats, roll-off containers, and roll-off trucks for the hauling and disposal of construction debris. This segment also offers full-scale commercial demolition and wrecking, as well as underground and above ground storage tank removal, and full-scale site clearing, including underground pipe removal and installation. The Insulation segment engages in the re-insulation and insulation of new and remodeling projects. CES Synergies, Inc. is also involved in the construction, installation, and repair of ceilings. The company serves city, state, and federal agencies, as well as general contractors, developers, project owners, and industrial and commercial clients. CES Synergies, Inc. was founded in 1988 and is headquartered in Crystal Springs, Florida.
Full CESX Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.